Tapinarof Cream
Tapinarof 1% cream (Vtama, now marketed by Organon) is a once-daily, steroid-free cream for Atopic Dermatitis. It is the first of a new class, the aryl hydrocarbon receptor (AhR) agonists. AhR is a sensor inside skin cells, and switching it on is thought to dampen inflammatory cytokines and support the skin barrier (unverified). The FDA label says “the specific mechanisms… are unknown”. Its first US licence was for adult Psoriasis. There is no traditional use. It joins Roflumilast Cream, Ruxolitinib Cream, Crisaborole and the Topical Calcineurin Inhibitors as an alternative to Topical Corticosteroids, and it does not cause Skin Atrophy.
Tapinarof Cream [treats] Atopic Dermatitis Tapinarof Cream [relates] Psoriasis Tapinarof Cream [relates] Topical Corticosteroids
Licensing for toddlers. The FDA approved Vtama for plaque psoriasis in adults in May 2022. Drugs@FDA lists the eczema efficacy supplement as approved on 12 December 2024. The current label (effective 28 May 2025) covers atopic dermatitis “in adults and pediatric patients 2 years of age and older”, with no severity limit in the wording. It is applied as a thin layer once daily. It is not licensed under 2 years. Neither the European Medicines Agency (no entry in the EMA medicines register, 3 October 2026) nor the UK (emc: “No search results for tapinarof”) has authorised tapinarof. The MHRA product search could not be loaded to confirm. So for UK and South African families it is effectively a US-only option for now.
FDA [regulates] Tapinarof Cream European Medicines Agency [relates] Tapinarof Cream MHRA [relates] Tapinarof Cream
Strength of evidence. ADORING 1 and ADORING 2 randomised 813 people with moderate-to-severe AD (median age 11, 80% aged 2–17) to tapinarof or a vehicle cream once daily for 8 weeks. “Clear or almost clear” with a 2-grade improvement was reached by 45–46% on tapinarof against 14–18% on vehicle (FDA label). The AAD Pediatric Guideline 2026 strongly recommends tapinarof from age 2. It is the only one of the new non-steroid creams graded high certainty: EASI-75 RR 2.60, itch response RR 1.77, vIGA-AD success RR 2.89. The AAD notes that no paediatric-only analysis met its inclusion criteria, so the evidence is mixed-age. The trials did not compare tapinarof with topical steroids. Tapinarof is not in NICE CG57.
AAD Pediatric Guideline 2026 [supports] Tapinarof Cream
Toddler safety. The most distinctive side effect is Folliculitis, meaning small pustules around hair follicles: 9% against 1% on vehicle in the eczema trials, and 20% in the adult psoriasis trials. The label’s folliculitis grouping also includes Keratosis Pilaris and follicular eczema. Other side effects more common than with vehicle were upper respiratory infection (12% vs 6%), lower respiratory infection (5% vs 2%), headache, Asthma or wheeze (2% vs 0%), vomiting, and ear infection (2% vs 0%). The label says upper respiratory and ear infections were more frequent in children than in adults. Application-site reactions were the same as vehicle (3.5% vs 3.3%). There is no boxed warning and no contraindication. The AAD says the risk of follicular reactions should be discussed when prescribing.
Tapinarof Cream [causes] Folliculitis Tapinarof Cream [relates] Asthma
What parents report. Parent reports for toddlers are thin (evidence: anecdotal). One parent whose 2-year-old was prescribed Vtama saw no clear change after 4 days, with the child still itching, and planned a 2-week trial. They added that it is “super hard with a toddler” because the child cannot say whether she has side effects (evidence: anecdotal). Another parent used it on their son only during flares, “so far so good” (evidence: anecdotal). Neither reported a later outcome.
Parent Experiences [relates] Tapinarof Cream
Connections
- Atopic Dermatitis — treats AD from age 2, source: FDA VTAMA label 2025
- FDA — AD supplement approved 12 Dec 2024; ≥2 y, source: Drugs@FDA; FDA label
- European Medicines Agency — no EU authorisation, source: EMA medicines report 2026-10-03
- MHRA — no UK SmPC on emc, source: emc search 2026-10-03
- AAD Pediatric Guideline 2026 — strong rec ≥2 y, high certainty, source: JAAD 2026
- Folliculitis — 9% vs 1% (AD trials), source: FDA label
- Keratosis Pilaris — counted within label’s folliculitis grouping, source: FDA label
- Asthma — asthma/wheeze 2% vs 0% in ADORING, source: FDA label
- Psoriasis — original indication (adults), source: FDA label
- Roflumilast Cream — other new non-steroid cream from 2 y, source: AAD 2026
- Ruxolitinib Cream — other new non-steroid cream from 2 y, source: AAD 2026
- Crisaborole — older non-steroid alternative, from 3 months, source: AAD 2026
- Topical Calcineurin Inhibitors — steroid-sparing comparator, source: AAD 2026
- Topical Corticosteroids — no head-to-head trial, source: AAD 2026
- Skin Barrier Dysfunction — proposed AhR barrier effect, source: vault synthesis
- NICE CG57 — not covered, source: NICE CG57
- Parent Experiences — 2-year-old trial report, source: Reddit r/eczema